作者
Agnes Lezin, Nicolas Gillet, Stéphane Olindo, Aïssatou Signaté, Nathalie Grandvaux, Olivier Verlaeten, Gildas Belrose, Marcelo de Carvalho Bittencourt, John Hiscott, Becca Asquith, Arsène Burny, Didier Smadja, Raymond Césaire, Luc Willems
发表日期
2007/11/15
期刊
Blood, The Journal of the American Society of Hematology
卷号
110
期号
10
页码范围
3722-3728
出版商
American Society of Hematology
简介
Epigenetic modifications of chromatin may play a role in maintaining viral latency and thus persistence of the human T-lymphotropic virus type 1 (HTLV-1), which is responsible for HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP). A major determinant of disease progression is increased peripheral blood proviral load (PVL), possibly via the accumulation of infected cells in the central nervous system (CNS) creating a damaging inflammatory response. Current therapeutic approaches that focus on reducing either cell proliferation, viral replication, or tissue invasion are still unsatisfactory. Contrasting with these inhibitory strategies, we evaluated the efficacy of a novel approach aimed, paradoxically, at activating viral gene expression to expose virus-positive cells to the host immune response. We used valproate (VPA), a histone deacetylase inhibitor that has been used for decades as a chronic …
引用总数
2007200820092010201120122013201420152016201720182019202020212022202320242711215113811495557121
学术搜索中的文章